These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 37198888)

  • 1. Rapid response of generalized pustular psoriasis to treatment with risankizumab. A therapeutic option for a difficult-to-treat disease.
    May Lee M; Fantini C; Mori E; Feliciani C; Satolli F
    Ital J Dermatol Venerol; 2023 Aug; 158(4):377-378. PubMed ID: 37198888
    [No Abstract]   [Full Text] [Related]  

  • 2. Generalized Pustular Psoriasis Treated With Risankizumab.
    Song EJ
    Cutis; 2023 Feb; 111(2):96-98. PubMed ID: 37075177
    [No Abstract]   [Full Text] [Related]  

  • 3. Generalized pustular psoriasis of pregnancy treated with infliximab.
    Sheth N; Greenblatt DT; Acland K; Barker J; Teixeira F
    Clin Exp Dermatol; 2009 Jun; 34(4):521-2. PubMed ID: 19196309
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy and safety of risankizumab in Japanese patients with generalized pustular psoriasis or erythrodermic psoriasis: Primary analysis and 180-week follow-up results from the phase 3, multicenter IMMspire study.
    Yamanaka K; Okubo Y; Yasuda I; Saito N; Messina I; Morita A
    J Dermatol; 2023 Feb; 50(2):195-202. PubMed ID: 36514850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of Risankizumab in Asian Healthy Subjects and Patients With Moderate to Severe Plaque Psoriasis, Generalized Pustular Psoriasis, and Erythrodermic Psoriasis.
    Khatri A; Eckert D; Oberoi R; Suleiman A; Pang Y; Cheng L; Othman AA
    J Clin Pharmacol; 2019 Dec; 59(12):1656-1668. PubMed ID: 31257614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risankizumab: First Global Approval.
    McKeage K; Duggan S
    Drugs; 2019 Jun; 79(8):893-900. PubMed ID: 31098898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generalized pustular psoriasis flare in a patient affected by plaque psoriasis after BNT162b2 mRNA COVID-19 vaccine, successfully treated with risankizumab.
    Pavia G; Gargiulo L; Spinelli F; Avagliano J; Valenti M; Borroni RG; Costanzo A; Narcisi A
    J Eur Acad Dermatol Venereol; 2022 Jul; 36(7):e502-e505. PubMed ID: 35224780
    [No Abstract]   [Full Text] [Related]  

  • 8. Successful treatment of Von Zumbusch pustular psoriasis with infliximab.
    Trent JT; Kerdel FA
    J Cutan Med Surg; 2004; 8(4):224-8. PubMed ID: 16091999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute generalized pustular psoriasis successfully treated with the IL-23p19 antibody risankizumab.
    Heyer S; Seiringer P; Eyerich S; Pilz AC; Steimle-Grauer SA; Eyerich K; Biedermann T; Böhner A
    J Dtsch Dermatol Ges; 2022 Oct; 20(10):1362-1364. PubMed ID: 36067528
    [No Abstract]   [Full Text] [Related]  

  • 10. Risankizumab-induced paradoxical pustular psoriasis.
    McFeely O; Pender E; Victory L; Almutlaq H; Storan E
    Clin Exp Dermatol; 2022 Mar; 47(3):616-617. PubMed ID: 34748673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exposure-Response Relationships for the Efficacy and Safety of Risankizumab in Japanese Subjects with Psoriasis.
    Suleiman AA; Khatri A; Oberoi RK; Othman AA
    Clin Pharmacokinet; 2020 May; 59(5):575-589. PubMed ID: 31667790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generalized pustular psoriasis: the new era of treatment with IL-36 receptor inhibitors.
    Maçães CO; Lé AM; Torres T
    J Dermatolog Treat; 2022 Nov; 33(7):2911-2918. PubMed ID: 35695278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis.
    Haugh IM; Preston AK; Kivelevitch DN; Menter AM
    Drug Des Devel Ther; 2018; 12():3879-3883. PubMed ID: 30518998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risankizumab: A Review in Moderate to Severe Plaque Psoriasis.
    Blair HA
    Drugs; 2020 Aug; 80(12):1235-1245. PubMed ID: 32632826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of spesolimab in Asian patients with a generalized pustular psoriasis flare: Results from the randomized, double-blind, placebo-controlled Effisayil™ 1 study.
    Morita A; Tsai TF; Yee EYW; Okubo Y; Imafuku S; Zheng M; Li L; Quaresma M; Thoma C; Choon SE
    J Dermatol; 2023 Feb; 50(2):183-194. PubMed ID: 36282833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A dramatic response to a single dose of infliximab as rescue therapy in acute generalized pustular psoriasis of von Zumbusch associated with a neutrophilic cholangitis.
    Chandran NS; Chong WS
    Australas J Dermatol; 2010 Feb; 51(1):29-31. PubMed ID: 20148838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiological survey of patients with pustular psoriasis in the Japanese Society for Psoriasis Research from 2017 to 2020.
    Kamiya K; Ohtsuki M
    J Dermatol; 2023 Jan; 50(1):3-11. PubMed ID: 36152301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adalimumab effectively controlled recalcitrant generalized pustular psoriasis in an adolescent.
    Callen JP; Jackson JH
    J Dermatolog Treat; 2005; 16(5-6):350-2. PubMed ID: 16428160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on risankizumab for the treatment of moderate to severe psoriasis.
    Al-Janabi A; Warren RB
    Expert Opin Biol Ther; 2020 Nov; 20(11):1245-1251. PubMed ID: 32933320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid and sustained response to spesolimab in five Chinese patients with generalized pustular psoriasis.
    Ran D; Yang B; Sun L; Wang N; Qu P; Liu J; Pan F; Wang G; Wu W; Zhang Z; Shi Z; Yang Q; Liu H; Zhang F
    Clin Exp Dermatol; 2023 Jul; 48(7):803-805. PubMed ID: 36994823
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.